Aberrant upregulation of the glycolytic enzyme PFKFB3 in CLN7 neuronal ceroid lipofuscinosis

CLN7 neuronal ceroid lipofuscinosis is an inherited lysosomal storage neurodegenerative disease highly prevalent in children. CLN7/MFSD8 gene encodes a lysosomal membrane glycoprotein, but the biochemical processes affected by CLN7-loss of function are unexplored thus preventing development of potential treatments. Here, we found, in the Cln7∆ex2 mouse model of CLN7 disease, that failure in autophagy causes accumulation of structurally and bioenergetically impaired neuronal mitochondria. In vivo genetic approach reveals elevated mitochondrial reactive oxygen species (mROS) in Cln7∆ex2 neurons that mediates glycolytic enzyme PFKFB3 activation and contributes to CLN7 pathogenesis. Mechanistically, mROS sustains a signaling cascade leading to protein stabilization of PFKFB3, normally unstable in healthy neurons. Administration of the highly selective PFKFB3 inhibitor AZ67 in Cln7∆ex2 mouse brain in vivo and in CLN7 patients-derived cells rectifies key disease hallmarks. Thus, aberrant upregulation of the glycolytic enzyme PFKFB3 in neurons may contribute to CLN7 pathogenesis and targeting PFKFB3 could alleviate this and other lysosomal storage diseases

NF-κB Activity Initiates Human ESC-Derived Neural Progenitor Cell Differentiation by Inducing a Metabolic Maturation Program

Human neural development begins at embryonic day 19 and marks the beginning of organogenesis. Neural stem cells in the neural tube undergo profound functional, morphological, and metabolic changes during neural specification, coordinated by a combination of exogenous and endogenous cues. The temporal cell signaling activities that mediate this process, during development and in the postnatal brain, are incompletely understood. We have applied gene expression studies and transcription factor-activated reporter lentiviruses during in vitro neural specification of human pluripotent stem cells. We show that nuclear factor κB orchestrates a multi-faceted metabolic program necessary for the maturation of neural progenitor cells during neurogenesis. In this research article, FitzPatrick and colleagues have highlighted the requirement for NF-κB signaling in neural specification of human embryonic stem cells. They demonstrate that its activity orchestrates a metabolic shift toward oxidative phosphorylation in committing neural progenitor cells. Moreover, they demonstrate that progenitor cells with increased endogenous NF-κB activity have a higher propensity for maturation

Partida de um reator anaeróbio horizontal para tratamento de efluentes do processamento dos frutos do cafeeiro Start-up of an anaerobic horizontal-flow reactor for treating wastewater from a coffee fruits processing

O presente estudo teve o objetivo de avaliar a partida e a adaptação de um reator anaeróbio horizontal de leito fixo (RAHLF) no tratamento de águas residuárias do processamento primário dos frutos do cafeeiro (ARC). O reator foi construído com tubos de PVC de 0,2 m de diâmetro e 3,2 m de comprimento. O sistema foi preenchido com cubos de espuma de poliuretano para imobilização de biomassa ativa. O reator apresentou volume total de 0,1 m³ e volume útil equivalente a 0,04 m³. Em média, houve remoção de 49% da matéria orgânica, com o reator trabalhando sob carga orgânica volumétrica média de 2,66 kg m-3 d-1, medida como DQO. A suplementação de alcalinidade, somada à inoculação prévia de biomassa, proporcionou partida estável do RAHLF, confirmada pelo consumo de ácidos voláteis e adaptação da microbiota ao resíduo. O sistema apresentou resistência às variações de vazão e de carga orgânica observadas, e os teores de fenol e potássio monitorados não causaram inibição da atividade biológica no RAHLF. O maior controle sobre as variações de carga é fator importante na continuidade dos estudos.<br>This study aimed to evaluate the start-up and the adaptation of an anaerobic horizontal-flow immobilized biomass (HAIB) reactor in order to treat wastewater from a primary processing of coffee fruits. The reactor was built with PVC tubes of 0.2 m in diameter and 3.2 m in length. The system was filled with cubes of polyurethane foam for immobilization of active biomass. The reactor presented a total capacity of 0.1 m³ and reaction volume equal to 0.04 m³. 49% of organic matter. Removal efficiency was observed, with medium organic volumetric loads equal to 2.66 kg m-3 d-1 (as chemical oxygen demand). The supplementary addition of alkalinity and the previous biomass inoculation provided a stable start-up of the reactor, as confirmed by the reduction of volatile acids and an adaptation of the present microbiology community. The systems showed resistance to changes in flow and in the organic load observed; the levels of phenol and potassium monitored did not cause inhibition of the biological activity. A better control on the changes in load rates is an important topic for the next studies

A decade of changes in management of immune thrombocytopenia, with special focus on elderly patients.

Ten years after their availability, thrombopoietin receptor agonists (TPO-RA) have heralded a paradigm shift in the treatment of immune thrombocytopenia (ITP). This study was aimed to analyze the implementation of current recommendations in the standard practice of adult ITP patients, and how age may influence those changes. We included 121 adult patients (> 65 years, n = 54; younger individuals, n = 67) who initiated treatment with TPO-RA between January 2012 and December 2014. Patients older than 65 years treated with TPO-RA presented at diagnosis with significantly higher platelet counts, less bleeding, and a more prothrombotic profile than younger ones. The high efficacy rates of TPO-RA, preferentially used during the last decade in non-chronic phases, precluded from further therapies in the majority of ITP patients. Their administration was associated with a sharp decline in the last decade in the use of splenectomy and intravenous immunoglobulin, especially in younger ITP individuals. These results confirm (1) that there is a preferential use of TPO-RAs in elderly ITP patients with fewer bleeding complications but more unfavorable prothrombotic conditions than in younger individuals, and (2) that early use of these agents has been established as an effective therapeutic alternative to other second line therapies

Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia.

Very few data exist on when a particular thrombopoietin-receptor agonist (TPO-RA) is favored in clinical practice for the treatment of patients with immune thrombocytopenia (ITP), about novel risk factors for vascular events (VE) with these drugs, nor about predictive factors for therapy free responses (TFR). We conducted an observational, retrospective, long-term follow-up multicenter study from November 2016 to January 2018 of 121 adult ITP patients initiating TPO-RA between January 2012 to December 2014. Data reflected that a platelet count ≤25 × 109/l at the time when the TPO-RA was initiated was associated with a 2.8 higher probability of receiving romiplostim vs. eltrombopag (P = 0.010). VE on TPO-RA was related to previous neoplasia in patients over 65 years (50% vs. 2.2%, P